Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 2, 2012, Pages 173-180

  Gronbaek H ^a   Sandahl, T D ^a   Mortensen, C ^b   Vilstrup, H ^a   Moller H J ^a   Moller S ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEART OUTPUT; HEPATIC VENOUS PRESSURE GRADIENT; HUMAN; KUPFFER CELL; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER VEIN; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PORTAL HYPERTENSION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC CIRCULATION; TARGET CELL; VASCULAR RESISTANCE; VEIN CATHETERIZATION; VENOUS PRESSURE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CARDIAC OUTPUT; CASE-CONTROL STUDIES; HUMANS; HYPERTENSION, PORTAL; KUPFFER CELLS; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PORTAL PRESSURE; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX;

EID: 84862532351     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05134.x     Document Type: Article

References (32)

1. Goulis J, Patch D, Burroughs AK,. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353: 139-42. (Pubitemid 29088094)
2. Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P,. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995; 108: 1828-34.
3. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK,. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54: 556-63. (Pubitemid 40395508)
4. Lin RS, Lee FY, Lee SD, et al,. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-72.
5. Ruiz-del-Arbol L, Urman J, Fernandez J, et al,. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 1210-8. (Pubitemid 37314829)
6. Perez del P, Pizcueta P, Engel P, Bosch J,. Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension. J Hepatol 2000; 32: 25-31. (Pubitemid 30039443)
7. Albillos A, Hera-Ad AL, Reyes E, et al,. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 2004; 40: 624-31. (Pubitemid 38367784)
8. Cohen JI, Nagy LE,. Pathogenesis of alcoholic liver disease: interactions between parenchymal and non-parenchymal cells. J Dig Dis 2011; 12: 3-9.
9. Steib CJ, Hartmann AC, v Hesler C, et al,. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest 2010; 90: 1024-32.
10. Steib CJ, Gerbes AL, Bystron M, et al,. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol 2007; 47: 228-38. (Pubitemid 47021253)
11. Weaver LK, Hintz-Goldstein KA, Pioli PA, et al,. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006; 80: 26-35. (Pubitemid 44835523)
12. Moestrup SK, Moller HJ,. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004; 36: 347-54. (Pubitemid 39233102)
13. Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK,. Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol 2010; 88: 1201-5.
14. Moller HJ, de FM, Aerts H, Hollak C, Moestrup SK,. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004; 72: 135-9. (Pubitemid 38161162)
15. Schaer DJ, Schleiffenbaum B, Kurrer M, et al,. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005; 74: 6-10. (Pubitemid 40143680)
16. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M,. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract 2005; 201: 379-84. (Pubitemid 40862463)
17. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M,. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 2005; 40: 52-6. (Pubitemid 40796332)
18. Moller HJ, Gronbaek H, Schiodt FV, et al,. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007; 47: 671-6. (Pubitemid 47503425)
19. Holland-Fischer P, Gronbaek H, Sandahl TD, et al,. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011; 60: 1389-93.
20. Moller S, Bendtsen F, Henriksen JH,. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.
21. Moller S, Hillingso J, Christensen E, Henriksen JH,. Arterial hypoxaemia in cirrhosis: fact or fiction? Gut 1998; 42: 868-74. (Pubitemid 28277231)
22. Tygstrup N,. The galactose elimination capacity in relation to clinical and laboratory findings in patients with cirrhosis. Acta Med Scand 1964; 175: 291-300.
23. Moller HJ, Hald K, Moestrup SK,. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002; 62: 293-9.
24. Garcia-Pagan JC, De GA, Bosch J,. Review article: the modern management of portal hypertension-primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008; 28: 178-86. (Pubitemid 351861966)
25. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC,. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009; 6: 573-82.
26. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK,. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002; 99: 378-80. (Pubitemid 34533008)
27. Steib CJ,. Kupffer cell activation and portal hypertension. Gut 2011; 60: 1307-8.
28. Tilg H, Wilmer A, Vogel W, et al,. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
29. Kaser A, Ludwiczek O, Waldenberger P, Jaschke W, Vogel W, Tilg H,. Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting. Liver 2002; 22: 380-7. (Pubitemid 35331398)
30. Gao B, Bataller R,. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-85.
31. Gao B, Seki E, Brenner DA, et al,. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011; 300: G516-25.
32. Cubero FJ, Urtasun R, Nieto N,. Alcohol and liver fibrosis. Semin Liver Dis 2009; 29: 211-21.